Shaheen Kurani1, Molly Moore Jeffery2, Bjorg Thorsteinsdottir3,4, LaTonya J Hickson3,5, Erin F Barreto3,6, Jordan Haag6, Rachel Giblon3, Nilay D Shah2,3, Rozalina G McCoy7,8,9. 1. Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA. 2. Division of Health Care Policy & Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 3. Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA. 4. Division of Community Internal Medicine, Department of Medicine, Mayo Clinic, First Street SW, Rochester, MN, USA. 5. Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA. 6. Department of Pharmacy, Mayo Clinic, Rochester, MN, USA. 7. Division of Health Care Policy & Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. mccoy.rozalina@mayo.edu. 8. Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA. mccoy.rozalina@mayo.edu. 9. Division of Community Internal Medicine, Department of Medicine, Mayo Clinic, First Street SW, Rochester, MN, USA. mccoy.rozalina@mayo.edu.
Abstract
BACKGROUND: People with chronic kidney disease (CKD) are at risk for adverse events and/or CKD progression with use of renally eliminated or nephrotoxic medications. OBJECTIVE: To examine the prevalence of potentially inappropriate medication (PIM) use by U.S. adults by CKD stage and self-reported CKD awareness. DESIGN: Cross-sectional analysis of National Health and Nutrition Examination Surveys, 2011-2016 PARTICIPANTS: Non-pregnant adults with stages 3a (eGFR 45-59 mL/min/1.73 m2), 3b (eGFR 30-44), or 4-5 (eGFR < 30) CKD, stratified as CKD-aware/unaware. MAIN MEASURES: PIMs were identified on the basis of KDIGO guidelines, label information, and literature review. We calculated proportions using any and individual PIMs, assessing for differences over CKD awareness within each CKD stage. Analyses were adjusted for age, sex, race/ethnicity, education, comorbidities, and insurance type. KEY RESULTS: Adjusted proportions of U.S. adults taking any PIM(s) exceeded 50% for all CKD stages and awareness categories, and were highest among CKD-unaware patients with stages 4-5 CKD: 66.6% (95% CI, 55.5-77.8). Proton pump inhibitors, opioids, metformin, sulfonylureas, and non-steroidal anti-inflammatory drugs (NSAIDs) were all used frequently across CKD stages. NSAIDs were used less frequently when CKD-aware by patients with stage 3a CKD (2.2% [95% CI, - 0.3 to 4.7] vs. 10.7% [95% CI, 7.6 to 13.8]) and stages 4-5 CKD (0.8% [95% CI, - 0.9 to 2.5] vs. 16.5% [95% CI, 4.0 to 29.0]). Metformin was used less frequently when CKD-aware by patients with stage 3b CKD (8.1% [95% CI, 0.3-15.9] vs. 26.5% [95% CI, 17.4-35.7]) and stages 4-5 CKD (none vs. 20.8% [95% CI, 1.8-39.8]). The impact of CKD awareness was statistically significant after correction for multiple comparisons only for NSAIDs in stage 3a CKD. CONCLUSIONS: PIMs are frequently used by people with CKD, with some impact of CKD awareness on NSAID and metformin use. This may lead to adverse outcomes or hasten CKD progression, reinforcing the need for improved medication management among people with CKD.
BACKGROUND:People with chronic kidney disease (CKD) are at risk for adverse events and/or CKD progression with use of renally eliminated or nephrotoxic medications. OBJECTIVE: To examine the prevalence of potentially inappropriate medication (PIM) use by U.S. adults by CKD stage and self-reported CKD awareness. DESIGN: Cross-sectional analysis of National Health and Nutrition Examination Surveys, 2011-2016 PARTICIPANTS: Non-pregnant adults with stages 3a (eGFR 45-59 mL/min/1.73 m2), 3b (eGFR 30-44), or 4-5 (eGFR < 30) CKD, stratified as CKD-aware/unaware. MAIN MEASURES: PIMs were identified on the basis of KDIGO guidelines, label information, and literature review. We calculated proportions using any and individual PIMs, assessing for differences over CKD awareness within each CKD stage. Analyses were adjusted for age, sex, race/ethnicity, education, comorbidities, and insurance type. KEY RESULTS: Adjusted proportions of U.S. adults taking any PIM(s) exceeded 50% for all CKD stages and awareness categories, and were highest among CKD-unaware patients with stages 4-5 CKD: 66.6% (95% CI, 55.5-77.8). Proton pump inhibitors, opioids, metformin, sulfonylureas, and non-steroidal anti-inflammatory drugs (NSAIDs) were all used frequently across CKD stages. NSAIDs were used less frequently when CKD-aware by patients with stage 3a CKD (2.2% [95% CI, - 0.3 to 4.7] vs. 10.7% [95% CI, 7.6 to 13.8]) and stages 4-5 CKD (0.8% [95% CI, - 0.9 to 2.5] vs. 16.5% [95% CI, 4.0 to 29.0]). Metformin was used less frequently when CKD-aware by patients with stage 3b CKD (8.1% [95% CI, 0.3-15.9] vs. 26.5% [95% CI, 17.4-35.7]) and stages 4-5 CKD (none vs. 20.8% [95% CI, 1.8-39.8]). The impact of CKD awareness was statistically significant after correction for multiple comparisons only for NSAIDs in stage 3a CKD. CONCLUSIONS: PIMs are frequently used by people with CKD, with some impact of CKD awareness on NSAID and metformin use. This may lead to adverse outcomes or hasten CKD progression, reinforcing the need for improved medication management among people with CKD.
Authors: Amy W Williams; Amy C Dwyer; Allison A Eddy; Jeffrey C Fink; Bertrand L Jaber; Stuart L Linas; Beckie Michael; Ann M O'Hare; Heidi M Schaefer; Rachel N Shaffer; Howard Trachtman; Daniel E Weiner; And Ronald J Falk Journal: Clin J Am Soc Nephrol Date: 2012-09-13 Impact factor: 8.237
Authors: Derk C F Klatte; Alessandro Gasparini; Hong Xu; Pietro de Deco; Marco Trevisan; Anna L V Johansson; Björn Wettermark; Johan Ärnlöv; Cynthia J Janmaat; Bengt Lindholm; Friedo W Dekker; Josef Coresh; Morgan E Grams; Juan J Carrero Journal: Gastroenterology Date: 2017-06-02 Impact factor: 22.682
Authors: Allison B McCoy; Lemuel R Waitman; Cynthia S Gadd; Ioana Danciu; James P Smith; Julia B Lewis; Jonathan S Schildcrout; Josh F Peterson Journal: Am J Kidney Dis Date: 2010-08-14 Impact factor: 8.860
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Laura C Plantinga; L Ebony Boulware; Josef Coresh; Lesley A Stevens; Edgar R Miller; Rajiv Saran; Kassandra L Messer; Andrew S Levey; Neil R Powe Journal: Arch Intern Med Date: 2008-11-10
Authors: Alessandro Bosi; Yunwen Xu; Alessandro Gasparini; Björn Wettermark; Peter Barany; Rino Bellocco; Lesley A Inker; Alex R Chang; Mara McAdams-DeMarco; Morgan E Grams; Jung-Im Shin; Juan J Carrero Journal: Clin Kidney J Date: 2021-10-29
Authors: Heather Personett May; Abby K Krauter; Dawn M Finnie; Rozalina Grubina McCoy; Kianoush B Kashani; Joan M Griffin; Erin F Barreto Journal: BMJ Open Date: 2022-06-22 Impact factor: 3.006